AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAY 29 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - A strategy of cotransfecting dendritic cells with lymphotactin gene and melanoma antigen can enhance the way the cells target melanoma tumor growth.
Several studies have shown where dendritic cells hold the potential for being powerful tumor vaccines. Study authors say that lymphotactin (Lptn), a chemoattractant for T cells and natural killer cells, increases the anticancer effect of T cells and boosts immune system responsiveness to cancer cell challenge in murine models of established melanoma when it is transfected along with melanoma-associated antigen gp100 into murine bone marrow dendritic cells.
D.J. Xia and colleagues, Zhejiang University, Hanzhou, China, found that in mice immunized with the Lptn/gp100-transfected dendritic cells (DC), cytotoxic T lymphocyte activity increased significantly, with natural killer (NK) cell activity increasing to a lesser extent. In addition, the study team detected significantly increased levels of two cytokines associated with antigen processing, interleukin (IL)-2 and interferon-(gamma).
In contrast, murine models inoculated with normal saline or with dendritic cells encoding for Lptn alone, gp100 alone, or control genes did not display such marked changes (Lymphotactic contransfection enhances the therapeutic efficacy of dendritic cells genetically modified ...